CinCor Pharma, Inc美股招股说明书 S-1 （2022-01-03修订版）（英文版）（242页）.pdf

1、S-1/A 1 d501326ds1a.htm S-1/ATable of ContentsAs filed with the Securities and Exchange Commission on January 3,2022.Registration No.333-261738UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549AMENDMENT NO.2TOFORM S-1REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF 1933CinCor Pharma

2、,Inc.(Exact name of registrant as specified in its charter)Delaware 2834 36-4931245(State or other jurisdiction ofincorporation or organization)(Primary Standard IndustrialClassification Code Number)(I.R.S.EmployerIdentification No.)200 Clarendon Street,6th FloorBoston,MA 02116(844)531-1834(Address,

3、including zip code,and telephone number,including area code,of registrants principal executive offices)Marc de GaridelChief Executive OfficerCinCor Pharma,Inc.200 Clarendon Street,6th FloorBoston,MA 02116(844)531-1834(Name,address,including zip code,and telephone number,including area code,of agent

4、for service)Copies to:Ryan SansomDivakar GuptaCourtney T.ThorneCooley LLP500 Boylston StreetBoston,MA 02116(617)937-2300 Lisa FirenzeRyan S.BrewerWilmer Cutler Pickering Hale&Dorr LLP7 World Trade Center250 Greenwich StreetNew York,NY 10007(212)230-8800Approximate date of commencement of proposed sa

5、le to the public:As soon as practicable after this Registration Statement is declared effective.If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933,check the followingbox.If this Form is filed

6、 to register additional securities for an offering pursuant to Rule 462(b)under the Securities Act,please check the following box and list the Securities Actregistration statement number of the earlier effective registration statement for the same offering.If this Form is a post-effective amendment